<DOC>
	<DOCNO>NCT02141204</DOCNO>
	<brief_summary>The purpose study evaluate compare immunogenicity , reactogenicity safety two formulation ( liquid vs. lyophilise ) GSK Biologicals ' HRV vaccine administer two dos healthy infant age ≥ 6 week .</brief_summary>
	<brief_title>Immunogenicity Safety Study Two Different Formulations Human Rotavirus Vaccine , Rotarix Healthy Infants</brief_title>
	<detailed_description>This protocol summary amend base NDAC- Vaccines ( New Drug Advisory Committee Vaccines ) Drugs Controller General India ( DCGI ) 's recommendation conduct study Phase IV study instead phase III , Rotarix liquid file application consider line extension Rotarix Lyophilized formulation .</detailed_description>
	<mesh_term>Rotavirus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe parent ( ) /Legally Acceptable Representative ( ) comply requirement protocol . A male female , include , 6 10 week age time first vaccination . Written inform consent obtain parent ( ) / Legally Acceptable Representative ( ) subject . Healthy subject establish medical history clinical examination enter study . Birth weight &gt; 2000 g. Child care . Use investigational nonregistered product study vaccine within 30 day precede first dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug since birth . Inhaled topical steroid allow . Administration chronic drug therapy continue study period . Planned administration/administration vaccine foreseen study protocol within 30 day first dose study vaccine exception routine childhood vaccination . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product . History confirm RV GE . Previous vaccination RV . Any confirm suspected immunosuppressive immunodeficient condition , ( include Severe Combined Immunodeficiency disorder ) base medical history physical examination . Uncorrected congenital malformation ( Meckel 's diverticulum ) gastrointestinal tract would predispose Intussusception history Intussusception . Family history congenital hereditary immunodeficiency . History reaction hypersensitivity likely exacerbate component vaccine . Major congenital defect serious chronic illness . History neurological disorder seizure . Acute disease and/or fever time enrolment . Fever define temperature ≥ 37.5°C /99.5°F oral , axillary tympanic setting , ≥ 38.0°C /100.4°F rectal setting . The preferred route record temperature study axillary . Subjects minor illness ( mild diarrhoea , mild upper respiratory infection ) without fever may , enrol discretion investigator ( warrant deferral vaccination ) . Acute chronic , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination medical history . Administration immunoglobulins and/or blood product since birth plan administration study period . GE within 7 day precede study vaccine administration .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>10 Weeks</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>HRV</keyword>
	<keyword>Liquid vaccine</keyword>
	<keyword>Human rotavirus vaccine</keyword>
</DOC>